Michel Kazatchkine

Michel Kazatchkine's AcademicInfluence.com Rankings

Michel Kazatchkine

Biology

#2470

World Rank

#3908

Historical Rank

Immunology

#137

World Rank

#144

Historical Rank

biology Degrees

Michel Kazatchkine

Philosophy

#4089

World Rank

#6477

Historical Rank

Logic

#1838

World Rank

#2689

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Michel Kazatchkine's Degrees

Doctorate Medicine Université Paris Cité
Masters Immunology Université Paris Cité

Why Is Michel Kazatchkine Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Michel Kazatchkine is a French physician, diplomat and advocate who is best known for his work in international AIDS treatment issues. From February 2007 to March 2012 he was director of The Global Fund to Fight AIDS, Tuberculosis and Malaria. On July 20, 2012, UN Secretary-General Ban Ki-moon appointed him as his United Nations Special Envoy for HIV/AIDS in Eastern Europe and Central Asia.

(See a Problem?)

Michel Kazatchkine's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. (2001) (1179)
Cutting Edge: Human CD4+CD25+ T Cells Restrain the Maturation and Antigen-Presenting Function of Dendritic Cells1 (2004) (532)
ANTI-IDIOTYPIC SUPPRESSION OF AUTOANTIBODIES TO FACTOR VIII (ANTIHAEMOPHILIC FACTOR) BY HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN (1984) (484)
Natural autoantibodies. (1995) (445)
Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy (2000) (428)
Public health and international drug policy (2016) (406)
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. (1979) (370)
Self-reactive antibodies (natural autoantibodies) in healthy individuals. (1998) (343)
High Prevalence of Anal Human Papillomavirus Infection and Anal Cancer Precursors among HIV-Infected Persons in the Absence of Anal Intercourse (2003) (318)
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. (2003) (311)
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial (2004) (304)
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. (2008) (292)
Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. (1998) (267)
A call to action for comprehensive HIV services for men who have sex with men (2012) (260)
Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action (2007) (257)
Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. (1991) (247)
Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. (1985) (239)
Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. (1989) (238)
Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. (1989) (234)
Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease (1998) (231)
Meeting the Demand for Results and Accountability: A Call for Action on Health Data from Eight Global Health Agencies (2010) (220)
Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. (1985) (219)
Early regression of cervical lesions in HIV‐seropositive women receiving highly active antiretroviral therapy (1998) (212)
Mechanisms of action of intravenous immune globulin in immune‐mediated diseases (1996) (204)
An action agenda for HIV and sex workers (2015) (201)
Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. (1987) (199)
Catalytic activity of antibodies against factor VIII in patients with hemophilia A (1999) (195)
Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission (2018) (193)
Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. (1993) (181)
Anti‐idiotypes against Autoantibodies in Normal Immunoglobulins: Evidence for Network Regulation of Human Autoimmune Responses (1989) (181)
The global response to HIV in men who have sex with men (2016) (179)
Anti‐idiotypes against anti‐neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis (1991) (179)
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b (1979) (177)
Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. (1995) (177)
C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. (1987) (176)
High Prevalence of Anal Squamous Intraepithelial Lesions in HIV-Positive Men Despite the Use of Highly Active Antiretroviral Therapy (2004) (173)
Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus. (1982) (170)
Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. (2001) (168)
Enhanced: The Need for a Global HIV Vaccine Enterprise (2003) (168)
Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS). (1990) (167)
Increased Risk of Cervical Disease Among Human Immunodeficiency Virus–Infected Women With Severe Immunosuppression and High Human Papillomavirus Load (2000) (165)
Catalytic Activity of Anti‐Thyroglobulin Antibodies a (1995) (164)
What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. (2014) (156)
In vivo induction of interleukin-1 during hemodialysis. (1989) (155)
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. (1981) (155)
Time to act: a call for comprehensive responses to HIV in people who use drugs (2010) (155)
Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. (1992) (154)
Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. (1996) (154)
Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. (1987) (152)
V Region‐Mediated Selection of Autoreactive Repertoires by Intravenous Immunoglobulin (i.v.Ig) (1994) (151)
Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. (1990) (145)
Human complement factor H deficiency associated with hemolytic uremic syndrome. (1998) (141)
Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women (2002) (138)
Analysis of the normal human IgG antibody repertoire. Evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissues. (1995) (137)
Common variable immunodeficiency is associated with defective functions of dendritic cells. (2004) (136)
Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. (2000) (136)
Activation of the complement system at the interface between blood and artificial surfaces. (1988) (134)
Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg) (1993) (132)
Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). (1994) (130)
Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases (1991) (130)
Mapping of the Region of Complement Receptor (CR) 1 Required for Plasmodium falciparum Rosetting and Demonstration of the Importance of CR1 in Rosetting in Field Isolates1 (2000) (129)
Expression and control of the natural autoreactive IgG repertoire in normal human serum (1993) (128)
Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin (2005) (124)
Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases (2003) (124)
Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. (1988) (124)
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination (2008) (122)
The Impact of HIV Antiviral Therapy on Human Papillomavirus (Hpv) Infections and Hpv-Related Diseases (2004) (120)
A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes (2007) (119)
Renal lesions in HIV-1-positive patient treated with tenofovir. (2003) (119)
Natural antibodies sustain differentiation and maturation of human dendritic cells. (2004) (115)
Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. (1999) (114)
Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. (2003) (114)
Selective induction of interleukin‐1 receptor antagonist and interleukin‐8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin) (1995) (114)
Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion (1991) (114)
Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). (1999) (113)
Binding sites for endotoxins (lipopolysaccharides) on human monocytes. (1991) (113)
Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. (2001) (111)
High levels of catalytic antibodies correlate with favorable outcome in sepsis. (2005) (111)
Analysis of the natural human IgG antibody repertoire: life‐long stability of reactivities towards self antigens contrasts with age‐dependent diversification of reactivities against bacterial antigens (1995) (111)
The prevalence of proteolytic antibodies against factor VIII in hemophilia A. (2002) (110)
Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. (1992) (109)
Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action (2007) (109)
Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. (1997) (105)
Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. (2000) (104)
Immunohistochemical study of the C5b-9 complex of complement in human kidneys. (1986) (100)
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? (2004) (98)
The Self‐Reactive Antibody Repertoire of Normal Human Serum IgM is Acquired in Early Childhood and Remains Conserved Throughout Life (1996) (96)
Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: a randomized prospective study. (1991) (95)
Delayed occurrence of Graves' disease after immune restoration with HAART (1998) (94)
AIDS: lessons learnt and myths dispelled (2009) (93)
The complement system in atherosclerosis. (1988) (92)
On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy (1990) (91)
Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). (1992) (90)
Modulation of Dendritic Cell Maturation and Function by B Lymphocytes1 (2005) (89)
Normal human serum contains natural antibodies reactive with autologous ABO blood group antigens. (1999) (88)
Opsonization of HIV-1 by Semen Complement Enhances Infection of Human Epithelial Cells (2002) (87)
The expanding epidemic of HIV-1 in the Russian Federation (2017) (87)
Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. (2007) (85)
Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. (2006) (84)
Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed. (1994) (83)
Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and RANTES correlate with virus load in human immunodeficiency virus infection. (1997) (83)
Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals (2006) (83)
Compartmentalization of HIV-1 between breast milk and blood of HIV-infected mothers. (2002) (82)
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. (2000) (81)
Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy (2000) (81)
Role of natural antibodies in immune homeostasis: IVIg perspective. (2008) (81)
Vienna Declaration: a call for evidence-based drug policies (2010) (80)
The Human Alternative Complement Pathway : Biology and Immunopathology of Activation and Regulation1 (1982) (80)
Population dynamics of natural antibodies in normal and autoimmune individuals. (1991) (78)
Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients (2001) (78)
DC-SIGN and α2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells (2009) (78)
Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. (1993) (77)
CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement‐opsonized HIV independently of CD4 (1993) (75)
Distribution in clusters of complement receptor type one (CR1) on human erythrocytes. (1989) (75)
The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives. (1988) (73)
Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. (1995) (73)
Antibodies to C-C Chemokine Receptor 5 in Normal Human IgG Block Infection of Macrophages and Lymphocytes with Primary R5-Tropic Strains of HIV-11 (2001) (72)
Autoantibodies against C1q: view on clinical relevance and pathogenic roles (1999) (72)
Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. (1981) (71)
Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus. (1994) (71)
Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12–26 study (2003) (71)
Deficiency of the adhesive protein complex lymphocyte function antigen 1, complement receptor type 3, glycoprotein p150,95 in a girl with recurrent bacterial infections. Effects on phagocytic cells and lymphocyte functions. (1985) (71)
Persistent Expansion, in a Human Immunodeficiency Virus-Infected Person, of Vβ-Restricted CD4+CD8+ T Lymphocytes that Express Cytotoxicity-Associated Molecules and Are Committed to Produce Interferon-γ and Tumor Necrosis Factor-α (1998) (71)
HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 alpha in vitro. (1989) (70)
Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. (2000) (70)
Intravenous Immunoglobulin Therapy of Autoimmune and Systemic Inflammatory Diseases (1993) (70)
Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. (2002) (70)
High Rate of Recurrence of Cervical Intraepithelial Neoplasia After Surgery in HIV-Positive Women (2005) (69)
Secretory Leukocyte Protease Inhibitor Inhibits Infection of Monocytes and Lymphocytes with Human Immunodeficiency Virus Type 1 but Does Not Interfere with Transcytosis of Cell-Associated Virus across Tight Epithelial Barriers (2000) (69)
Autoimmunity : physiology and disease (1993) (68)
Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. (2001) (67)
Stability of Natural Self-Reactive Antibody Repertoires During Aging (2004) (66)
gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway. (1988) (65)
Functional role of the alpha-chain of complement receptor type 3 in human eosinophil-dependent antibody-mediated cytotoxicity against schistosomes. (1987) (65)
Active and Selective Transcytosis of Cell-Free Human Immunodeficiency Virus through a Tight Polarized Monolayer of Human Endometrial Cells (2001) (65)
Anticomplementary activity of dextran derivatives. (1985) (65)
Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. (1991) (64)
Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. (1988) (64)
Membrane molecules which trigger the production of interleukin‐1 and tumor necrosis factor‐α by lipopolysaccharide‐stimulated human monocytes (1992) (64)
Analysis of human self-reactive antibody repertoires by quantitative immunoblotting. (2000) (63)
Opsonization of HIV with Complement Enhances Infection of Dendritic Cells and Viral Transfer to CD4 T Cells in a CR3 and DC-SIGN-Dependent Manner1 (2007) (62)
Bleeding in renal failure: a possible cause. (1976) (62)
Relative inefficiency of terminal complement activation. (1988) (62)
Autoantibodies to heat shock protein 90 in the human natural antibody repertoire. (2002) (61)
Autoantibodies to the collagen-like region of C1q are strongly associated with classical pathway-mediated hypocomplementemia in systemic lupus erythematosus (1996) (61)
Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. (1983) (60)
Induction of cell‐associated interleukin 1 through stimulation of the adhesion‐promoting proteins LFA‐1 (CD11a/CD18) and CR3 (CD11b/CD18) of human monocytes (1990) (60)
Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin‐reactive CD4+ T cells in healthy individuals (2001) (60)
Molecular weight dependency of the acquired anticomplementary and anticoagulant activities of specifically substituted dextrans. (1987) (60)
Dissociation between the interleukin 1-inducing capacity and Limulus reactivity of lipopolysaccharides from gram-negative bacteria. (1990) (60)
Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system (2002) (59)
Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. (1994) (59)
Comparative assessment of five alternative methods for CD4+ T-lymphocyte enumeration for implementation in developing countries. (2001) (59)
Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein (1998) (58)
Lipid peroxidation in human immunodeficiency virus infection. (1992) (58)
Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies (1990) (57)
Regulation of the human alternative complement pathway: formation of a ternary complex between factor h, surface‐bound c3b and chemical groups on nonactivating surfaces (1989) (57)
Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. (2009) (57)
Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. (2003) (56)
Gender differences in CD4+ cell counts persist after HIV‐1 infection (1997) (56)
Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study. (1989) (55)
Mouse monoclonal antibodies to the human C3b receptor. (1985) (55)
Catalytic IgG from Patients with Hemophilia A Inactivate Therapeutic Factor VIII1 (2006) (54)
Persistent expansion, in a human immunodeficiency virus-infected person, of V beta-restricted CD4+CD8+ T lymphocytes that express cytotoxicity-associated molecules and are committed to produce interferon-gamma and tumor necrosis factor-alpha. (1998) (54)
Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex. (1989) (54)
Polyreactivity is a Property of Natural and Disease‐Associated Human Autoantibodies (1993) (53)
Circulating immune complexes containing anti-VIII antibodies in multi-transfused patients with haemophilia A. (1980) (53)
A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. (2001) (52)
Induction of IL-1 release through stimulation of the C3b/C4b complement receptor type one (CR1, CD35) on human monocytes. (1990) (52)
Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. (1987) (52)
Shortage of human intravenous immunoglobulin—reasons and possible solutions (2007) (52)
Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. (2000) (51)
Altered control of self-reactive IgG by autologous IgM in patients with warm autoimmune hemolytic anemia. (2000) (51)
Nomenclature of amyloid and amyloidosis (1998) (50)
Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. (2000) (50)
Internalization pathway of C3b receptors in human neutrophils and its transmodulation by chemoattractant receptors stimulation. (1991) (50)
Human T cells and interleukin 4 inhibit the release of interleukin 1 induced by lipopolysaccharide in serumfree cultures of autologous monocytes (1989) (50)
Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line. (1988) (50)
Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south (2004) (49)
Dendritic cells and autoimmunity. (2004) (49)
Human eosinophils express CR1 and CR3 complement receptors for cleavage fragments of C3. (1986) (49)
Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. (1987) (49)
Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. (2004) (48)
Restoration of normal interleukin-2 production by CD4+ T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy. (1999) (48)
Induction of Apoptosis of Endothelial Cells by Viscum album: A Role for Anti-Tumoral Properties of Mistletoe Lectins (2002) (48)
Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice (1999) (48)
Genomic determination of the CR1 (CD35) density polymorphism on erythrocytes using polymerase chain reaction amplification and HindIII restriction enzyme digestion. (1991) (47)
High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. (2000) (47)
Papanicolaou Smears in Human Immunodeficiency Virus–Seropositive Women During Follow‐Up (1995) (46)
A V region‐connected autoreactive subfraction of normal human serum immunoglobulin G (1992) (46)
Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. (2006) (46)
Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis (1993) (46)
Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis (2019) (46)
Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. (2003) (45)
Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. (1996) (45)
Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. (1991) (45)
Immunoglobulins and the regulation of autoimmunity through the immune network. (1996) (45)
Compartmentalization of the IgG immune response to HIV-1 in breast milk. (1999) (44)
Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection (2005) (43)
Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 x 10(6) cells/l following combination antiretroviral therapy including protease inhibitors. (1997) (43)
Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE) (1992) (43)
Genital and oral erosions induced by foscarnet (1990) (43)
Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor. (1986) (43)
Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer (2008) (42)
Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum. (1988) (42)
Hypocomplementemic urticarial vasculitis syndrome, Jaccoud's syndrome, valvulopathy: a new syndromic combination. (1993) (41)
Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. (1995) (41)
Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. (1992) (41)
Molecular Mechanisms Underlying the Immunomodulatory Effects of Mistletoe (Viscum album L.) Extracts Iscador (2006) (41)
Enumeration of CR1 complement receptors on erythrocytes using a new method for detecting low density cell surface antigens by flow cytometry. (1987) (41)
Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. (1994) (41)
Detection of Y Chromosome DNA as Evidence of Semen in Cervicovaginal Secretions of Sexually Active Women (2001) (41)
Complement activation by gp160 glycoprotein of HIV-1. (1993) (40)
Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases (2007) (40)
Natural Antibodies to CCR5 from Breast Milk Block Infection of Macrophages and Dendritic Cells with Primary R5-Tropic HIV-11 (2005) (40)
Soluble CD16 Inhibits CR3 (CD11b/CD18)-Mediated Infection of Monocytes/Macrophages by Opsonized Primary R5 HIV-11 (2001) (39)
A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg) (1997) (39)
Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. (2004) (39)
Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells. (1998) (39)
Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: insights from modeling. (2014) (39)
Promoting Country Ownership and Stewardship of Health Programs: The Global Fund Experience (2009) (39)
Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. (1987) (39)
CR1(CD35) and CR2(CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus (1994) (39)
Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS. (2002) (39)
Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. (2008) (38)
A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines and idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). (1990) (38)
The concept of anti-idiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. (1989) (38)
Modulation of autoimmune responses by intravenous immunoglobulin (IVIg) (1997) (38)
Evidence for the Role of CR1 (CD35), in addition to CR2 (CD21), in Facilitating Infection of Human T Cells with Opsonized HIV (1993) (37)
Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm (2003) (37)
Complement activation and cytokine production as consequences of immunological bioincompatibility of extracorporeal circuits. (1993) (37)
Dissociation between complement activation, integrin expression and neutropenia during hemodialysis. (1999) (36)
Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells. (1991) (36)
Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome. (1999) (36)
Expression of CR1 (CD35) mRNA in podocytes from adult and fetal human kidneys. (1990) (36)
Decreased Expression of the Membrane Inhibitor of Complement‐Mediated Cytolysis CD59 on T‐lymphocytes of HIV‐Infected Patients (1992) (36)
Platelet-activating factor enhances complement-dependent phagocytosis of diamide-treated erythrocytes by human monocytes through activation of protein kinase C and phosphorylation of complement receptor type one (CR1). (1989) (36)
Inhibition of HIV‐1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC‐SIGN purified from breast milk and intravenous immunoglobulins (2008) (36)
Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein‐Barr virus receptor, CR2) that binds iC3b and CD23 (1996) (36)
Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). (1994) (36)
Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. (2000) (36)
Platelet‐dependent induction and amplification of polymorphonuclear leucocyte lysosomal enzyme release (1989) (35)
Nomenclature for T-cell receptor (TCR) gene segments of the immune system (1995) (35)
Evaluation of Thromboxane Production and Complement Activation During Myocardial Ischemia in Patients With Angina Pectoris (1991) (35)
Life-threatening intracranial bleeding associated with the presence of an antifactor VII autoantibody. (1989) (35)
Binding of LFA-1 (CD11a) to Intercellular Adhesion Molecule 3 (ICAM-3; CD50) and ICAM-2 (CD102) Triggers Transmigration of Human Immunodeficiency Virus Type 1-Infected Monocytes through Mucosal Epithelial Cells (2002) (35)
Gender difference in CD4+ cell counts persist after HIV-1 infection. SEROCO Study Group. (1997) (35)
Expression of CD21 is developmentally regulated during thymic maturation of human T lymphocytes. (1999) (34)
Double‐blind placebo‐controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease (2001) (34)
Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. (2007) (33)
Complement Receptor Type 2 Mediates Infection of the Human CD4‐Negative Raji B‐Cell Line with Opsonized HIV (1992) (33)
Shortage of human intravenous immunoglobulin—reasons and possible solutions (2008) (32)
Alterations of self-reactive antibody repertoires in HIV disease: an insight into the role of T cells in the selection of autoreactive B cells. (2005) (32)
Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells. (1982) (32)
Induction in Mucosa of IgG and IgA Antibodies against Parenterally Administered Soluble Immunogens (2001) (32)
Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients (2000) (32)
Evidence for a restricted idiotypic and epitopic specificity of anti‐thyroglobulin autoantibodies in patients with autoimmune thyroiditis (1991) (32)
Genetic analysis of CR1 expression on erythrocytes of patients with systemic lupus erythematosus. (1989) (32)
Immunohistochemical study of Ia antigen in the normal and diseased human kidney. (1984) (32)
Contraceptive Use in HIV-Positive Women (2004) (31)
Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. (2001) (31)
Lupus‐specific kidney deposits of HSP90 are associated with altered IgG idiotypic interactions of anti‐HSP90 autoantibodies (2002) (31)
Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1 (2007) (31)
Problems with condom use not unusual among men who have sex with men. (2014) (31)
Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy (2005) (30)
Regulation by sulphonate groups of complement activation induced by hydroxymethyl groups on polystyrene surfaces. (1993) (30)
Lysine residues, but not carbohydrates, are required for the regulatory function of H on the amplification C3 convertase of complement. (1984) (30)
The human C3b receptor (CR1). (1989) (30)
Extracapillary proliferative glomerulonephritis so-called malignant glomerulonephritis. (1972) (30)
Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins. (1989) (30)
Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. (1993) (29)
Induction of interleukin-1 during hemodialysis. (1993) (29)
Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individuals. (1989) (29)
Immunohistochemical analysis of C3 cleavage fragments, factor H, and the C5b-9 terminal complex of complement in de novo membranous glomerulonephritis occurring in patients with renal transplant. (1986) (29)
Pathophysiology of catalytic antibodies. (2006) (29)
Variable Sensitivity of Lymphoblastoid Cells to Apoptosis Induced by Viscum album Qu FrF, a Therapeutic Preparation of Mistletoe Lectin (2001) (29)
The human alternative complement pathway: biology and immunopathology of activation and regulation. (1982) (29)
Pathophysiology of inhibitors to factor VIII in patients with haemophilia A (2002) (29)
Autoreactive Antibody Repertoire Is Perturbed in Atherosclerotic Patients (2003) (29)
‘Time is costly’: modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa (2008) (29)
Modulation of human dendritic cell maturation and function by natural IgG antibodies. (2008) (28)
Anti-cardiolipin antibodies are associated with anti-endothelial cell antibodies but not with anti-beta 2 glycoprotein I antibodies in HIV infection. (1995) (28)
Soluble CD21 induces activation and differentiation of human monocytes through binding to membrane CD23 (1998) (27)
Intravenous immunoglobulin in neurological disorders: a mechanistic perspective (2005) (27)
Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. (1994) (27)
Pathogenesis of dengue: an alternative hypothesis. (1990) (27)
Biocompatibility of extracorporeal circuits in heart surgery. (1990) (26)
Tuberculosis and HIV: time for an intensified response (2010) (26)
Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. (1999) (26)
Anti-C3b-receptor (CR1) antibodies in patients with systemic lupus erythematosus. (1986) (26)
IgM‐enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu‐SCID mice (2006) (26)
Russia’s ban on methadone for drug users in Crimea will worsen the HIV/AIDS epidemic and risk public health (2014) (26)
Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. (2005) (26)
Are lymphocytes concerned with our definition of idiotypes? (1993) (25)
Membrane-bound hemagglutinin mediates antibody and complement-dependent lysis of influenza virus-treated human platelets in autologous serum. (1984) (25)
Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric‐chloride‐induced autoimmune disease of Brown‐Norway rats (1991) (25)
Analysis of antibody reactivities toward self antigens of IgM of patients with Waldenström's macroglobulinemia. (1997) (25)
Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women. (2003) (24)
Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. (1996) (24)
Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. (1993) (23)
Suboptimal C3b/C3bi deposition and defective yeast opsonization. I. Evidence for the absence of essential co-factor activity. (1985) (23)
Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21). (1990) (23)
Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients (2006) (23)
Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report* from a meeting of the WHO-UNAIDS Vaccine Advisory Committee** Geneva, 21–23 February 2000 (2001) (22)
Polymerase chain reaction for Y chromosome to detect semen in cervicovaginal fluid: a prerequisite to assess HIV-specific vaginal immunity and HIV genital shedding. (2001) (22)
Treatment of autoimmune diseases with normal immunoglobulin through manipulation of the idiotypic network (1993) (22)
Secretory leukocyte protease inhibitor in colostrum and breast milk is not a major determinant of the protection of early postnatal transmission of HIV. (1999) (22)
Functional properties of soluble CD21. (1999) (22)
Effect of substituted dextran derivative on complement activation in vivo. (1995) (21)
Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. (1996) (21)
Instability of Natural Antibody Repertoires in Systemic Lupus Erythematosus Patients, Revealed by Multiparametric Analysis of Serum Antibody Reactivities (1997) (21)
Natural Autoantibodies to Fcγ Receptors in Intravenous Immunoglobulins (2014) (21)
Combined Heterozygous Deficiency of the Classical Complement Pathway Proteins C2 and C4 (1997) (21)
Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus (1992) (21)
Complement activation and induction of interleukin-1 production during hemodialysis. (1988) (21)
Normal human polyspecific immunoglobulin G (intravenous immunoglobulin) modulates endothelial cell function in vitro. (1995) (20)
Universal access to HIV treatment in developing countries: going beyond the misinterpretations of the ‘cost-effectiveness’ algorithm (2008) (20)
Ligation of CR1 (C3b receptor, CD35) on CD4+ T lymphocytes enhances viral replication in HIV‐infected cells (1996) (20)
Selective impairment of serum antibody repertoires toward muscle and thymus antigens in patients with seronegative and seropositive myasthenia gravis (1998) (20)
Restricted genetic defects underlie human complement C6 deficiency (2003) (20)
Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement. (1983) (20)
Genetically Related Human Immunodeficiency Virus Type 1 in Three Adults of a Family with No Identified Risk Factor for Intrafamilial Transmission (1998) (19)
Revisited indications for bone marrow examinations in HIV‐infected patients (1994) (19)
The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients. (2000) (19)
Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies (2018) (19)
Antiretroviral therapy suppresses the constitutive production of interleukin-1 associated with human immunodeficiency virus infection. (1995) (19)
Sulfonated dextran inhibits complement activation and complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. (1996) (19)
Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users. (1999) (19)
Lack of behavioural risk factors for squamous intraepithelial lesions (SIL) in HIV-infected women. (1997) (19)
Enhanced transcytosis of R5-tropic human immunodeficiency virus across tight monolayer of polarized human endometrial cells under pro-inflammatory conditions. (2002) (19)
Comparative Study of the Sensitivity of Lymphoblastoid and Transformed Monocytic Cell Lines to the Cytotoxic Effects of Viscum album Extracts of Different Origin (2003) (19)
Intravenous Immunoglobulin (IVIg) Modulates the Expansion of Vβ3+ and Vβ17+ T Cells Induced by Staphylococcal Enterotoxin B Superantigen In Vitro (1996) (19)
Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. (1993) (19)
The Global Fund's leadership on harm reduction: 2002-2009. (2010) (19)
Specific antibodies enhance alternative complement pathway activation by cuprophane. (1991) (18)
[Immunomodulatory effects of intravenous immunoglobulins]. (2000) (18)
[Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine]. (1997) (18)
Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor (1984) (18)
Monoclonal anti-idiotypic antibodies against human anti-thyroglobulin autoantibodies recognize idiotopes shared by disease-associated and natural anti-thyroglobulin autoantibodies. (1993) (17)
Can intravenous immunoglobulin treatment regulate autoimmune responses? (1992) (17)
Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases. (1994) (17)
Modulation by complement of immune complex processing in health and disease in man. (1986) (17)
The human C3b receptor. (1983) (17)
Restricted BV gene usage by factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A (2003) (17)
Age-related changes in specificity of human natural autoantibodies to thyroglobulin. (1993) (16)
Affinity-Purified Respiratory Syncytial Virus Antibodies from Intravenous Immunoglobulin Exert Potent Antibody-Dependent Cellular Cytotoxicity (2013) (16)
Sporotrichosislike infection caused by Mycobacterium avium in the acquired immunodeficiency syndrome. (1993) (16)
Effect of interferon and ribavirin on HIV viral load. (2000) (16)
Ontogenesis of the glomerular C3b receptor (CR1) in fetal human kidney. (1985) (16)
Intravenous immunoglobulin and immune response (2014) (16)
Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz. (2000) (16)
Efficacy and safety of desensitization to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. (1995) (16)
Autoantibodies to factor VIII. (2002) (16)
Human T lymphocytes expressing the C3b/C4b complement receptor type one (CR1, CD35) belong to Fc gamma receptor-positive CD4-positive T cells. (1989) (15)
High incidence of early postnatal transmission of human immunodeficiency virus type 1 in Bangui, Central African Republic. (1998) (15)
Maximizing the benefits of antiretroviral therapy for key affected populations (2014) (15)
Natural antibodies to factor VIII. (2000) (15)
Lack of evidence of a specific role for C4A gene deficiency in determining disease susceptibility among C4‐deficient patients with systemic lupus erythematosus (SLE) (2001) (15)
Clinical applications of intravenous immunoglobulin therapy: edited by Peng Lee Yap, Churchill Livingstone, 1992. £40 (ix + 270 pages) ISBN 0443 045887 (1993) (15)
Renal aspergilloma in AIDS. (1993) (15)
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights (2021) (15)
Intravenous immunoglobulin and dendritic cells (2005) (14)
Quantitation of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in Cell-Free Cervicovaginal Secretions: Comparison of Reverse Transcription-PCR Amplification (AMPLICOR HIV-1 MONITOR 1.5) with Enhanced-Sensitivity Branched-DNA Assay (Quantiplex 3.0) (2001) (14)
High Seroprevalence of Herpes Simplex Virus Type 2 Infection in French Human Immunodeficiency Virus Type 1-Infected Outpatients (2005) (14)
Idiotypic regulation of anti-factor VIII antibodies. (2000) (14)
Assessment of complement activation in clinical samples. Comparison of immunochemical and functional measurements of complement components with quantitation of activation fragments. (1992) (14)
Decreased expression of C3b receptor (CR1) on erythrocytes of patients with systemic lupus erythematosus contrasts with its normal expression in other systemic diseases and does not correlate with the occurrence or severity of SLE nephritis. (1986) (14)
Autoantibodies to factor VIII with catalytic activity. (2003) (14)
Isolation and characterization of the C3b-binding entity of C3b-receptor from human erythrocytes. (1982) (14)
Characterization of Monoclonal Antihuman‐B‐Cell Antibody BL13 as an Anti‐C3d‐Receptor (CR2) Antibody (1986) (14)
Normal IgG protects against acute graft‐versus‐host disease by targeting CD4+CD134+ donor alloreactive T cells (2001) (14)
Increased Polymorphism in the HR-1 gp41 env Gene Encoding the Enfuvirtide (T-20) Target in HIV-1 Variants Harboring Multiple Antiretroviral Drug Resistance Mutations in the pol Gene (2007) (13)
Expression of CRl and CR2 Complement Receptors following Epstein‐Barr Virus Infection of Burkitt's Lymphoma Cell Lines (1987) (13)
“Rational Vaccine Design” for HIV Should Take into Account the Adaptive Potential of Polyreactive Antibodies (2011) (13)
Modulation of HIV Binding to Epithelial Cells and HIV Transfer from Immature Dendritic Cells to CD4 T Lymphocytes by Human Lactoferrin and its Major Exposed LF-33 Peptide (2011) (13)
Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG (2000) (13)
Bacterial lipopolysaccharides alter human endothelial cell morphology in vitro independent of cytokine secretion. (1991) (13)
Immunohistochemical localization of S protein/vitronectin in human atherosclerotic versus arteriosclerotic arteries (2004) (13)
Mechanisms of Action of Intravenous Immunoglobulin (IVIG) (2000) (13)
Schistosoma mansoni: Activation of the alternative pathway of human complement by schistosomula (1980) (13)
Dilution assessment of cervicovaginal secretions collected by vaginal washing to evaluate mucosal shedding of free human immunodeficiency virus (1997) (13)
[Efficacy of intravenous immunoglobulin in the treatment of Birdshot retinochoroiditis]. (2002) (13)
Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants? (2007) (13)
Human diseases associated with C3 receptor deficiencies. (1987) (13)
Red blood cell transfusions are associated with alterations in self-reactive antibody repertoires of plasma IgM and IgG, independent of the presence of a specific immune response toward RBC antigens. (2002) (12)
Activation of the human classical complement pathway by a mouse monoclonal hybrid IgG1-2a monovalent anti-TNP antibody bound to TNP-conjugated cells. (1985) (12)
Efficacy and safety of combination therapy with interferon-a2b and ribavirin for chronic hepatitis C in HIV-infected patients (2000) (12)
Intravenous immunoglobulin for infectious diseases: tailor-made or universal? (2003) (12)
Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues. (2002) (12)
A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19 (2020) (12)
Neutralising antibodies against C3NeF in intravenous immunoglobulin (1992) (12)
The WHO we want (2020) (12)
The use of intravenous immunoglobulins in the treatment of factor VIII inhibitors. (1994) (12)
Complement C4A gene deletion in patients with systemic lupus erythematosus in France. (1993) (12)
Getting to grips with the HIV epidemic in Russia. (2019) (12)
Complement enhancement of HIV infection is mediated by complement receptors. (1993) (11)
IMMUNOMODULATION OF AUTOIMMUNE AND SYSTEMIC INFLAMMATORY DISEASES WITH INTRAVENOUS IMMUNOGLOBULIN (1994) (11)
Mechanisms and consequences of complement activation during hemodialysis. (1989) (11)
Broad Alterations of Self-Reactive Antibody-Repertoires of Plasma IgM and IgG in B-Cell Chronic Lymphocytic Leukemia (B-CLL) and B-CLL Related Target-Restricted Autoimmunity (2001) (11)
Modulation of the formation of the human amplification C3 convertase of complement by polycations. (1983) (11)
Immunological and virological features of HIV‐infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor‐based therapy (2002) (11)
Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases. (1993) (11)
Interactions between the alternative complement pathway and proteases of the coagulation system. (1984) (11)
[Lipoprotein anomalies in HIV infections]. (1996) (11)
Methods for assessing monocytic cytokine production as an index of biocompatibility. (1994) (10)
[Recurrent polyneuropathy with a 19-year course, associated with a benign IgG monoclonal gammapathy]. (1976) (10)
Multidrug-resistant HIV-1 RNA and proviral DNA variants harboring new dipeptide insertions in the reverse transcriptase pol gene. (2002) (10)
Antibodies with hydrolytic activity towards factor VIII in patients with hemophilia A. (2002) (10)
Didanosine Dosed Once Daily Is Equivalent to Twice Daily Dosing for Patients on Double or Triple Combination Antiretroviral Therapy (2000) (10)
15-HETE "modulates" expression of C3b receptor (CR1) antigen on peripheral blood B-lymphocytes. (1986) (10)
Anti-idiotypes against autoantibodies to procoagulant factor VIII (VIII:C) in intravenous immunoglobulins. (1989) (10)
[Decrease of erythrocyte receptors for the C3b fragment of complement in acquired immunodeficiency syndrome]. (1988) (10)
Role of laparoscopic surgery in the management of acute abdomen in the HIV-positive patients. (1995) (10)
An ELISA method to measure total and specific human secretory IgA subclasses based on selective degradation by IgA1-protease. (2000) (9)
Brussels Declaration: Twenty-point plan for science policy (2017) (9)
Mechanisms of immunomodulatory action of intravenous immunoglobulin in autoimmune and systemic inflammatory diseases. (1997) (9)
Altered antibody repertoires of plasma IgM and IgG toward nonself antigens in patients with warm autoimmune hemolytic anemia. (2001) (9)
Activation-dependent antigenic changes of human C3. (1989) (9)
New anionic polyelectrolyte hydrogel for corneal surgery. (1997) (9)
Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy. (1998) (9)
The cytolytic C5b-9 complement complex: feedback inhibition of complement activation. (1988) (9)
Dissociation between beta-2 microglobulin and IL-1 production in hemodialyzed patients. (1997) (9)
Drug use, HIV, HCV and TB: major interlinked challenges in Eastern Europe and Central Asia (2014) (9)
Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes. (2006) (9)
[Monoclonal antibodies against surface antigens of lymphoblasts and blood cells or bone marrow recognize constituents of the human nephron]. (1984) (9)
Low plasma levels of dehydroepiandrosterone (DHEA) and incidence of lipodystrophy (2001) (9)
The role of naturally-occurring antibodies against man-made materials in biocompatibility (1990) (9)
Vaccines, therapeutics, and diagnostics for covid-19: redesigning systems to improve pandemic response (2021) (9)
Intravenous immune globulin in autoimmune uveitis. (1998) (8)
State of the art science addressing injecting drug use, HIV and harm reduction. (2015) (8)
High frequency of C4 "null" alleles in primary antiphospholipid syndrome. (1996) (8)
Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in renal diseases: Loss of C3b receptor antigen in proliferate nephritis of sle (1982) (8)
Bartter's syndrome with normal chloride reabsorption during indomethacin treatment. (1987) (8)
Immunomodulation of Autoimmune Disease with Normal Polyspecific Immunoglobulin G (Intravenous Immunoglobulin) (1999) (8)
Effects of non-steroidal antiallergic eyedrops on the complement-mediated histamine release from human cells. (1997) (8)
Corrigendum to ‘Role of natural antibodies in immune homeostasis: IVIg perspective’ [Autoimmun. Rev. 7 (2008) 440–444] (2013) (8)
Anti-Idiotypes to Autoantibodies in Therapeutic Preparations of Normal Polyspecific Human IgG (Intravenous Immunoglobulin, IVIg) (1997) (7)
L’infection par le virus de l’hépatite C (2002) (7)
Idiopathic Membranous Glomerulonephritis Is Associated with Altered Patterns of Self‐reactive IgM and IgG Antibody Repertoires (2001) (7)
[Pneumocystis carinii pneumonia in a kidney transplantation center in the proximity of an AIDS care unit]. (1992) (7)
[Partial properdin deficiency revealed by a septicemia caused by Neisseria meningitidis]. (1995) (7)
Altered self-reactive antibody repertoires are a general feature of patients with myelodysplastic syndrome. (2001) (7)
Antibody-based therapies for COVID-19: Can Europe move faster? (2020) (7)
[Homozygotic C5 deficiency disclosed by purulent Neisseria meningitidis meningitis]. (1985) (7)
Enhancing role of complement in HIV infection (1994) (7)
The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research. (2005) (6)
Immunomodulation of Autoimmunity by Intravenous Immunoglobulin through Interaction with Immune Networks (2002) (6)
[Idiopathic CD4 lymphocytopenia]. (1994) (6)
[Intravenous immunoglobulins in autoimmune and inflammatory disorders: beyond a simple substitution]. (2009) (6)
Intravenous immunoglobulin (IVIg) modulates the expansion of V beta 3+ and V beta 17+ T cells induced by staphylococcal enterotoxin B superantigen in vitro. (1996) (6)
Reconstitution of self-reactive antibody repertoires of autologous plasma IgM in patients with non-Hodgkin's lymphoma following myeloablative therapy. (2001) (6)
Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines. (1987) (6)
[Factor I deficiency, a regulator protein of complement]. (1990) (6)
Natural autoantibodies: immune homeostasis and therapeutic intervention (2005) (6)
Catalytic antibodies to factor VIII in haemophilia A. (2003) (6)
Suboptimal C3b/C3bi deposition and defective yeast opsonization. II. Partial purification and preliminary characterization of an opsonic co-factor able to correct sera with the defect. (1985) (6)
The mechanism of action of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy. (1990) (6)
Analysis of self-reactive antibody repertoires in normal pregnancy. (1998) (6)
Complement-Mediated Injury (1986) (6)
Idiopathic thrombocytopenic purpura in patients at risk for acquired immunodeficiency syndrome. Histopathologic study, immunohistochemistry, and ultrastructural study on six spleens. (1988) (6)
Selective impairment of serum antibody repertoires toward muscle and thymus antigens in patients with seropositive and seronegative myasthenia gravis (1997) (6)
Editorial commentary: successful methadone delivery in East Africa and its global implications. (2014) (6)
IVIG and regulation of autoimmunity through the idiotypic network (1991) (6)
Modulation of Autoimmune Responses with Normal Polyspecific IgG for Therapeutic Use (1989) (5)
Transforming or tinkering: the world remains unprepared for the next pandemic threat (2022) (5)
Stopping epidemics when and where they occur (2023) (5)
Natural IgG autoantibodies in the sera of healthy individuals. (1994) (5)
[Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases]. (1999) (5)
The human glomerular C3 receptor. (1984) (5)
Complement and immunological disease (1988) (5)
[Alternative complement pathway]. (1983) (5)
The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A (2002) (5)
HIV in men who have sex with men 6 A call to action for comprehensive HIV services for men who have sex with men (2012) (5)
Intravenous Immunoglobulins in the Treatment of Autoimmune Diseases (1993) (5)
A call to reprioritise metrics to evaluate illicit drug policy (2016) (5)
Idiotypic modulation of autoimmunity by therapeutic human immunoglobulin preparations (IVIg). (1992) (4)
Ukrainian war: an economic crisis in Eastern Europe and Central Asia will lead to a health crisis (2022) (4)
Factor VIII inhibitor with catalytic activity towards factor VIII. (2000) (4)
Failure of antibiotic therapy in Staphylococcus epidermidis infection of implantable venous access devices in patients with AIDS, as documented by molecular typing. (1999) (4)
Fas Apoptotic Pathway Novel Mechanism of Action of IVIg Involving Human Lymphocytes and Monocytes : A Polyspecific IgG ( IVIg ) Induce Apoptosis in Therapeutic Preparations of Normal Ruberti (1998) (4)
Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G (2006) (4)
Apoptosis: The Relation between Anti-Fas antibodies, and Immunosurveillance Against Cancer and Autoimmunity (2000) (4)
Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz (2002) (4)
Towards a new health diplomacy in eastern Ukraine. (2017) (4)
Secretory immunoglobulins in serum from human immunodeficiency virus (HIV)-infected patients (1992) (4)
Prevention of experimental autoimmune uveoretinitis by infusions of human therapeutic intravenous immunoglobulins in rats. (1993) (4)
SDGs will not be achieved without drug policy reform (2015) (4)
Abnormal chromatin clumping in polymorphonuclears from a patient with AIDS (1996) (4)
[Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)]. (1996) (4)
Alterations in host defense mechanisms associated with cardiopulmonary bypass. (1986) (4)
A synthetic dextran derivative inhibits complement activation and complement-mediated cytotoxicity in an in vitro model of hyperacute xenograft rejection. (1996) (4)
Anti-idiotypic suppression of autoantibodies with high dose intravenous immunoglobulins. (1990) (4)
[Managing of an innovation in health care: the case of polyvalent intravenous immunoglobulins at the Assistance-Publique-Hôpitaux de Paris]. (1995) (3)
[Intravenous immunoglobulins (IgIV) in the treatment of autoimmune diseases and systemic inflammatory diseases]. (1993) (3)
Immunoglobulines intraveineuses (IVIg) et suppression anti-idiotypique de l'auto-immunité (1992) (3)
[Immunomodulatory effects of intravenous immunoglobulins]. (2004) (3)
The role of complement in immune clearance of blood cells (2005) (3)
Increased resources for the Global Fund, but pledges fall short of expected demand (2010) (3)
The Role of Complement in Enhancing Infection of Target Cells with Human Immunodeficiency Virus (1993) (3)
Modulation of the formation of the human C3 amplification convertase of complement by polyelectrolytes (1981) (3)
Presence of the C3b complement receptor (CR1) antigen in the glomerular basement membrane of human fetal kidneys. (1988) (3)
Integrating HIV and substance misuse services: a person-centred approach grounded in human rights. (2022) (3)
Sustained high proportion of zidovudine‐resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors (2002) (3)
Bioincompatibility of artificial surfaces in extracorporeal circulation: Induction of interleukin-1 production during hemodialysis (1987) (3)
Zidovudine inhibits functional extracellular monocytic interleukin-1. (1990) (3)
Perspectives on harm reduction — what experts have to say (2010) (3)
Turning the world on its ear: defining milestones on the road to HAART (2008) (3)
Autoantibodies in Therapeutic Preparations of Human IgG (IVIg) (1996) (3)
Suppression of Autoimmunity through Manipulation of Immune Network with Normal Immunoglobulin G (1993) (3)
[Induction of interleukin-1 synthesis. A new criterion of biocompatibility of extracorporeal circuits]. (1991) (3)
Health in the Soviet Union and in the post-Soviet space: from utopia to collapse and arduous recovery (2017) (3)
Reasons for drug policy reform: people who use drugs are denied evidence based treatment (2017) (3)
Leaders can choose to prevent pandemics (2022) (3)
Histiocytosis-X cells express C3b, C3d, and C3bi receptor (CR1, CR2, and CR3) antigens (2004) (3)
Twenty-point plan for science policy (2017) (3)
Successful treatment of HIV-related thrombocytopenia with didanosine (ddI) (1994) (3)
[The role of thrombosis in renal allograft rejection (author's transl)]. (1976) (3)
Methylprednisolone inhibits granulocytopenia induced by infusion of complement-activated serum but not of complement-activated plasma in rabbits. (1989) (3)
Primary cardiac lymphoma in patients with AIDS. (1995) (3)
TERMINOLOGY NOTE: INTERLEUKIN 16 (IL-16) (1997) (3)
Guinea pig erythrocytes after their contact with influenza virus, activate the human alternative pathway through virus-induced desialation of the cells (1982) (2)
Lessons and myths in the HIV/AIDS response – Authors' reply (2009) (2)
Delineating Physiological (Natural) Autoreactivity from Pathological Autoimmunity (1996) (2)
HIV-1 Dendritic Cells with Primary R 5-Tropic Milk Block Infection of Macrophages and Natural Antibodies to CCR 5 from Breast Belec and (2005) (2)
[Anti-idiotype suppression of autoimmunity by therapeutic intravenous immunoglobulins]. (1988) (2)
[The complement system in hepatopathies]. (1985) (2)
Catalytic activity of anti-thyroglobulin antibodies. (1995) (2)
Variable (V) region-mediated control of autoreactivity to factor VIII. (1995) (2)
[Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases]. (1993) (2)
[Primary pulmonary hypertension in human immunodeficiency virus infection. Study of 9 cases amd review of the literature]. (2001) (2)
[Acalculous cholangitis and cholecystitis in two AIDS patients]. (1991) (2)
Decreased levels of complement components C4 and C2 in lupus erythematosus: genetic defect or complement activation? (1984) (2)
Foreword: illicit drugs in Central Asia. (2014) (2)
Complete inherited deficiency of the fourth complement component in a child with systemic lupus erythematosus and his disease-free brother in a North African family (1994) (2)
Drug policy and human rights in the Middle East and North Africa: Harm reduction, legal environment and public health. (2016) (2)
[Splenic infarction in a HIV-infected patient. Apropos of a case and review of the literature]. (1996) (2)
It is time for ambitious, transformational change to the epidemic countermeasures ecosystem (2023) (2)
HIV in people who use drugs 7 Time to act: a call for comprehensive responses to HIV in people who use drugs (2010) (2)
Comparative study ofin vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA) (1991) (2)
[Paroxysmal nocturnal hemoglobinuria. Increase in proteins of the alternative complement pathway]. (1983) (2)
Membrane and soluble forms of CD21 (the C3dg/EBV receptor). (1996) (2)
Cellular and molecular aspects of systemic autoimmunity (1993) (2)
The detection of CR1 mRNA and CR1 antigen identifies the presence of immature podocytes in a case of Wilms' tumor (nephroblastoma). (1993) (2)
[Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders]. (2007) (2)
The Global Fund expands its role. Interview by the Bulletin. (2007) (2)
[Desensitization to trimethoprim-sulfamethoxazole in patients with HIV infection]. (1996) (2)
End compulsory drug treatment in the Asia-Pacific region (2022) (2)
HIV in Asia: universal access in sight (2010) (2)
International drug control system: public health guiding principles (2019) (2)
Chapter 36 – Autoantibodies in Therapeutic Preparations of Human Intravenous Immunoglobulin (IVIg) (2014) (1)
The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load. (1998) (1)
[Embolism caused by cholesterol]. (1991) (1)
[Structure and function of receptors for C3 cleavage fragments]. (1991) (1)
Relationship between anticardiolipin, anti-endothelial cell and anti-β2-glycoprotein I antibodies in HIV-infected individuals (1995) (1)
Immunointervention for patients with HIV and tuberculosis. (2009) (1)
« Anticorps catalytiques ou abzymes / Catalytic activity of antibodies » (2015) (1)
Idiotype-Based Immunotherapy of Cancers (1997) (1)
Primary R 5 HIV-1 Monocytes / Macrophages by Opsonized ( CD 11 b / CD 18 )-Mediated Infection of Soluble CD 16 Inhibits CR 3 (2001) (1)
Is cancer an autoimmune process dependent on anti-apoptotic autoantibodies? (2000) (1)
[Components of the classical complement pathway in systemic lupus erythematosus]. (1987) (1)
Soluble trimeric CD23 and C3 fragments are associated with CD21 in normal human serum (1997) (1)
Human CD3 Complement Receptors (1988) (1)
Viral Transfer to CD 4 T Cells in a CR 3 and Enhances Infection of Dendritic Cells and Opsonization of HIV with Complement (2006) (1)
Anti idiotypic recognition of auto and allo antibodies to factor VIII by immunoglobulin preparations from single blood donors and large plasma pool. (1990) (1)
Anti-Idiotypic Regulation of the Alloimmune Response in Patients Transfused with Platelet Concentrates (1993) (1)
Hypocomplementaemia in a newborn caused by transplacental passage of maternal autoantibody with C3 nephritic factor (C3 NeF) activity. (1995) (1)
Mechanisms of action of IVIg (1997) (1)
Research in Action: From AIDS to Global Health to Impact. A Symposium in Recognition of the Scientific Contributions of Professor Joep Lange (2015) (1)
Immunological Processes in the Vascular Wall (1989) (1)
C3 receptor-mediated production and release of interleukin 1 by human monocytes. (1989) (1)
Antibodies to RGD-sequence containing integrin ligands, capable of inhibiting cellular adhesion interactions, are present in normal intravenous immunoglobulin (1997) (1)
[Activation of the complement system during extracorporeal circulation in cardiac surgery]. (1986) (1)
Modulation of Endothelial Cell Function by Normal Polyspecific Human Immunoglobulins (IVIg) (2001) (1)
Disseminated adenovirus 20 infection with pancreatitis in a patient with AIDS. (1996) (1)
Human platelets after their contact with influenza virus activate the complement system in autologous serum (1983) (1)
[Comparative action of carbamazepine and clofibrate in diabetes insipidus. Study of 7 cases]. (1975) (1)
The challenges of an HIV vaccine enterprise - Response (2004) (1)
[The alternative complement pathway]. (1983) (1)
[Activation of the alternative pathway of human complement (author's transl)]. (1982) (1)
IVIg in the treatment of patients with factor VIII inhibitors. (1995) (1)
[Reversible hyperaluminemia induced by ingestion of didanosine in a patient under chronic hemodialysis]. (1994) (1)
Corrigendum to “Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes” [Immunol. Lett. 107 (2006) 58–62] (2006) (1)
Anti-Inflammatory Effects of Intravenous Immunoglobulin (1999) (1)
Brief Common variable immunodeﬁciency is associated with defective functions of dendritic cells (2004) (0)
Archbishop Desmond Tutu and the universality of health and human rights (2022) (0)
autoimmune encephalomyelitis immunoglobulin: a critical factor in controlling experimental Expansion of CD4+CD25+ regulatory T cells by intravenous (2013) (0)
[Intravenous immunoglobulins and anti-idiotypic suppression of auto-immunity]. (1992) (0)
Biological Functions of Catalytic Antibodies (2003) (0)
Concerning ‘Hepatitis C Virus’ (Transfus Med Hemother2003;30:239–250) (2003) (0)
Polyspecific immunoglobulins protect from experimental allergic encephalomyelitis (EAE) (1997) (0)
The EU has a global health strategy: the challenge will be in the implementation (2023) (0)
Immunopathology of Immune Complex Disease (1983) (0)
Soluble CD21 enhances interleukein-4-induced IgE production by normal human B cells (1998) (0)
[Complement system]. (1987) (0)
[Role of the CR1 receptor for complement C3b fragment]. (1988) (0)
Contents Vol. 30, 2003 (2003) (0)
Super-Avidin-Biotin System for Detecting Low-Density Cell Surface Antigens by Flow Cytometry (1989) (0)
TOXIDERMIES A LA PYRIMETHAMINE CHEZ LES PATIENTS INFECTES PAR LE VIRUS DE L'IMMUNODEFICIENCE ACQUISE (1995) (0)
R 5-Tropic Strains of HIV-1 Macrophages and Lymphocytes with Primary Normal Human IgG Block Infection of Antibodies to C-C Chemokine Receptor 5 in Kaveri and (2001) (0)
Modification of the expression of the C3b receptor by 15-HETE (1985) (0)
Panel discussion on the development of inhibitors: Who and why? (1995) (0)
Activation of the Human Complement System by “Standard” Polymers (Eurobiomat) (1992) (0)
Title Page / Contents / Foreword (1988) (0)
Partner, participants and problem-solvers: Expanding from "Informed Consent" to "Informed Communities" in the Search for the AIDS Vaccine (2009) (0)
Ischemia in Patients With Angina Pectoris (2005) (0)
Contents Vol. 49, 2003 (2003) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
The ability of H to modulate C5 utilization by the cell-bound alternative pathway C5 convertase differs on sheep and rabbit erythrocytes (1983) (0)
[The urgency of deep institutional reforms in global health in the face of Covid-19 pandemic]. (2020) (0)
[Alternative complement pathway (author's transl)]. (1979) (0)
Deficiency of the Adhesive Protein Complex Lymphocyte Function Antigen 1 , Complement Receptor Type 3 , Glycoprotein p 150 , 95 in a Girl with Recurrent Bacterial Infections (2013) (0)
Natural Autoantibodies to Fcγ Receptors in Intravenous Immunoglobulins (2014) (0)
Subject Index Vol. 30, 2003 (2003) (0)
[Lupus and protein deficiencies of the classical complement pathway]. (1990) (0)
PLATELET-DEPENDENT ACTIVATION AND AMPLIFICATION OF THE POLYMORPHONUCLEAR LEUKOCYTES LYSOSOMAL ENZYME RELEASE (1987) (0)
Natural autoantibodies: Transplacental passage in humans (2002) (0)
Inhibition of Formation of the Human Amplification C3 Convertase by Fluid Phase Polycations (1982) (0)
[Median HIV viral load and incidence of Cytomegalovirus viremia. Improvement in a cohort of HIV-infected patients followed-up between January 1996 and April 1007]. (1998) (0)
[The detection of soluble immune complexes (author's transl)]. (1979) (0)
[Toxic dermatitis caused by pyrimethamine in patients with acquired immunodeficiency virus infection]. (1995) (0)
[Homozygous C6 deficiency disclosed by Streptococcus A infection]. (1986) (0)
[Immunomodulator effects of intravenous immunoglobulins in neurological autoimmune diseases]. (1995) (0)
Take One – Get Two: Automated Red Blood Cell Collection (2003) (0)
Natural IgG Anti-F (ab’)2 Autoantibody Activity in Children with Autism (2023) (0)
Epithelial Cells Complement Enhances Infection of Human Opsonization of HIV-1 by Semen (2002) (0)
What We Expect From the Policy-Making Community (2017) (0)
INTRAVENOUS IMMUNOGLOBULIN (IVIg) THERAPY OF AUTOIMMUNE DISEASES (1996) (0)
Delineating physiological (natural) autoreactivity from pathological autoimmunity. Discussion (1996) (0)
How Science Diplomacy Removes Political Barriers (2016) (0)
[Catalytic antibodies or "abzymes"]. (2003) (0)
Isolatesthe Importance of CR1 in Rosetting in Field Rosetting and Demonstration of falciparum Plasmodium Receptor (CR) 1 Required for Mapping of the Region of Complement (2000) (0)
Activation of the immune system during extracorporeal circulation (1989) (0)
Fourth European Workshop on Inflammation Wilrijk March 1982 (1982) (0)
Electron Microscopy Study of the Spleen in HIV-Infected Patients (1991) (0)
Phenotypic and functional studies of CD21 on human thymocytes (1998) (0)
[Acquired C1 esterase inhibitor deficiency, Gougerot-Sjögren syndrome and B lymphoma]. (1989) (0)
Use of a polypeptide having the activity of soluble human CD16 in the treatment of infection by the HIV virus (1995) (0)
Mechanisms of action of intravenous immunoglobulin (IVIg) in autoimmune and neuromuscular diseases. (1999) (0)
The Human Alternative Complement Pathway: Biology and Immunopathology of Activation and Regulation (Part 2 of 2) (1982) (0)
Opsonised immune complexes containing autoantigen and natural autoantibodies rescue peripheral blood B cells from apoptosis (2000) (0)
[Presence of the terminal complement activation complex (C5b-9) on cell remnants within connective matrices of normal human kidney]. (1983) (0)
Redoubling global efforts to support HIV/AIDS and human rights. (2010) (0)
CellsAntigen-Presenting Function of Dendritic Restrain the Maturation and T Cells + CD25+ Cutting Edge: Human CD4 (2004) (0)
Human C3 and C3dg Stimulate Proliferation of a Pre-B Lymphoblastoid Cell Line via CR2 Complement Receptor (1988) (0)
The Participation of the Complement System in Atherosclerotic Vascular Disease (1991) (0)
Serotonin Release from Filtered and Unfiltered Human Platelets Induced by Antigen/Antibody Complexes of Different Valencies (1977) (0)
Mechanisms of Action of Intravenous Immunoglobulin (IVIg) in Immune-Mediated Diseases (1999) (0)
[Complement, a system of recognition of activation and amplification]. (1982) (0)
Déficit homozygote en C6 révélé par une infection à streptocoque A. (1986) (0)
CHARGE VIRALE MEDIANE DU VIH ET INCIDENCE DES VIREMIES DU CYTOMEGALOVIRUS : DIMINUTION DANS UNE COHORTE DE PATIENTS INFECTES PAR LE VIH SUIVIS ENTRE J ANVIER 1996 ET AVRIL 1997 (1998) (0)
Epitope specificity of anti-factor VII antibodies in healthy individuals, in hemophilia patients and in patients with autoimmune disease (1997) (0)
[Research of the nephritic factor (C3 Nef) in the serum]. (1991) (0)
From The Lancet (1990) (0)
Panel discussion on the treatment of inhibitors: Today and tomorrow (1995) (0)
[Reduction of Willebrand activity in patients with chronic kidney failure]. (1976) (0)
Enhancing role ofcomplement inHIVinfection (1994) (0)
C5b-9 Complex of Complement Is Found in Subepithelial Deposits of Stage-i Idiopathic Membranous Nephropathy (imn), But Not of Stage-i Denovo Membranous Nephropathy (dnmn) and Toxic Induced Membranous Nephropathy (tmn) (1984) (0)
Factor VIII inhibitor with catalytic activity towards factor VIII. (2000) (0)
Corrigendum to “Intravenous immunoglobulin in autoimmune disorders: An insight into the immunoregulatory mechanisms” [Int. Immunopharmacol. 6 (2006) 528–534] (2013) (0)
[Access to treatment of HIV/AIDS in the South: the challenges of sustainability]. (2008) (0)
From bench to patients: We really can move mountains (2010) (0)
The HIV Epidemic: Living with AIDS (2006) (0)
Dendritic Cells with Primary R5-Tropic Milk Block Infection of Macrophages and Natural Antibodies to CCR5 from Breast (2013) (0)
Anticorps catalytiques ou abzymes (2003) (0)
Reply to Jefferis (1995) (0)
Natural autoantibodies and complement mediate B cell uptake of self antigens and their presentation to T cells (2000) (0)
Erratum to: Intravenous Immunoglobulin and Dendritic Cells (2014) (0)
Human C6 deficiency has a homogeneous genetic background (2000) (0)
Short review Pathophysiology of catalytic antibodies (2006) (0)
Immunological and Laboratory Aspects of Immune Tolerance (1996) (0)
Modulation of the formation of the human amplification c 3 convertase by poly cations (1981) (0)
Intravenous preparations of normal IgG (IVIg) induces apoptosis in human leukemic cells: A role for Fas and activation of caspases (1997) (0)

This paper list is powered by the following services:

Other Resources About Michel Kazatchkine

What Schools Are Affiliated With Michel Kazatchkine?

Michel Kazatchkine is affiliated with the following schools:

Michel Kazatchkine's Academic­Influence.com Rankings

Michel Kazatchkine's Degrees

Why Is Michel Kazatchkine Influential?

Michel Kazatchkine's Published Works

Published Works

Other Resources About Michel Kazatchkine

What Schools Are Affiliated With Michel Kazatchkine?

Image Attributions

Michel Kazatchkine's AcademicInfluence.com Rankings